Recommended

Learn how to optimize antibody leads in early drug discovery in this upcoming webinar! Register today!
Discover how artificial intelligence is transforming drug discovery in this innovative report! Download your very own copy now!
Discover how clinical research is evolving to deliver new therapies faster in our new exciting brand report!
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

AI-based smartphone app can predict user’s health risks

Researchers have developed AI based data analysis methods used in a smartphone app which can estimate its users’ health risks…

smartphone

VTT Technical Research Centre of Finland has developed artificial intelligence (AI)-based data analysis methods used in a smartphone application of Odum Ltd. The application can estimate its users’ health risks and, if necessary, guide them towards a healthier lifestyle.

“Based on an algorithm developed by VTT, we can predict the risk of illness-related absence from work among members of the working population over the next 12 months, with an up to 80 percent sensitivity,” says VTT’s Mark van Gils, the scientific coordinator of the project.

“This is a good example of how we can find new information insights that are concretely valuable to both citizens and health care professionals by analysing large and diverse data masses.”

The application also guides individuals at risk to complete an electronic health exam and take the initiative in promoting their own health.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Smartphone data

During the project Odum and VTT examined health data collected from 18-64 year-olds over the course of several years. The project received health data from a total of 120,000 working individuals.

“Health care costs are growing at an alarming pace and health problems are not being addressed early enough,” says Jukka Suovanen, CEO of Odum. “Our aim is to decrease illness-related absences by 30 percent among application users and add 10 healthy years to their lives.”

The most cost-efficient way to improve quality of life and decrease health care costs for both individuals and society is to promote the health of individuals and encourage them to take initiative in reducing their health risks.

VTT is one of the leading research and technology companies in Europe. We help our clients develop new technologies and service concepts in the areas of Digital Health, Wearable technologies and Diagnostics – supporting their growth with top-level research and science-based results.